Publicaciones en colaboración con investigadores/as de Hospital Miguel Servet (22)

2024

  1. Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

    Haematologica, Vol. 109, Núm. 1, pp. 115-128

2021

  1. 6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival

    British Journal of Haematology, Vol. 192, Núm. 5, pp. 843-852

  2. Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?

    Leukemia, Vol. 35, Núm. 6, pp. 1571-1585

  3. Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)

    PLoS ONE, Vol. 16, Núm. 9 September

  4. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia

    Leukemia, Vol. 35, Núm. 8, pp. 2358-2370

2020

  1. Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project

    Haematologica, Vol. Online ahead of print

2019

  1. Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population

    British Journal of Haematology, Vol. 185, Núm. 3, pp. 480-491

2018

  1. Basophil-lineage commitment in acute promyelocytic leukemia predicts for severe bleeding after starting therapy

    Modern Pathology, Vol. 31, Núm. 8, pp. 1318-1331

2017

  1. Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia

    Medicina Clinica, Vol. 148, Núm. 8, pp. 381.e1-381.e9

2016

  1. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under lendex: A longitudinal analysis

    Blood, Vol. 127, Núm. 9, pp. 1151-1162

  2. Sarcoma histiocítico en intestino delgado: estudio y discusión de un caso con reordenamiento clonal linfoide B

    Revista Espanola de Patologia, Vol. 49, Núm. 4, pp. 254-258

2015

  1. The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution

    Leukemia

2014

  1. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia

    British Journal of Haematology, Vol. 167, Núm. 4, pp. 466-477

2013

  1. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia

    Leukemia, Vol. 27, Núm. 8, pp. 1722-1728

2012

  1. Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4 and MLL-germline acute lymphoblastic leukemia

    Leukemia, Vol. 26, Núm. 11, pp. 2360-2366

  2. SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status

    Leukemia, Vol. 26, Núm. 12, pp. 2521-2529

2010

  1. BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)

    Annals of Hematology, Vol. 89, Núm. 5, pp. 453-458

  2. Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients

    Haematologica, Vol. 95, Núm. 5, pp. 745-751

2009

  1. High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics

    Leukemia Research, Vol. 33, Núm. 12, pp. 1706-1709

  2. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia

    Blood, Vol. 114, Núm. 1, pp. 148-152